Guidelines for the management of adult lower respiratory tract infections
Abstract
No risk factors for P. aeruginosa (see table 12) Nonantipseudomonal cephalosporin III+macrolide # or Nonantipseudomonal cephalosporin III+(moxifloxacin or levofloxacin) Risk factors for P. aeruginosa (see table 12) Anti-pseudomonal cephalosporin " or Acylureidopenicillin/b-lactamase inhibitor or Carbapenem + ciprofloxacin P. aeruginosa: Pseudomonas aeruginosa.# : new macrolides preferred to erythromycin; " : cefepime not ceftazidime.For recommended dosages see Appendix 3.
Read the paper
Related studies
- Impact of antibiotics on the human microbiome and consequences for host health
- Antibiotics in the clinical pipeline in October 2019
- The incidence of collagen-associated adverse events in pediatric population with the use of fluoroquinolones: a nationwide cohort study in Taiwan
- Research Communications of the 32nd ECVIM-CA Online Congress
- Singlet-Oxygen Therapy. Scientific And Methodological Materials
- Artificial Intelligence in Pharmacovigilance
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.